<DOC>
	<DOCNO>NCT00006036</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one chemotherapy drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness liposomal lurtotecan plus cisplatin treating patient advance metastatic solid tumor .</brief_summary>
	<brief_title>Liposomal Lurtotecan Plus Cisplatin Treating Patients With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose recommended phase II dose lurtotecan liposome cisplatin patient advance solid tumor . II . Determine toxicity profile , dose-limiting toxic effect , pharmacokinetics treatment regimen patient population . III . Determine correlation toxicity profile pharmacokinetics treatment regimen patient . IV . Determine objective tumor response treatment regimen patient measurable disease ( previously untreated solid tumor ) enter recommended phase II dose . OUTLINE : This open-label , multicenter , dose-escalation study lurtotecan liposome . Patients receive cisplatin IV 1 hour follow lurtotecan liposome IV 30 minute day 1-3 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Once total dose cisplatin reach , patient receive lurtotecan liposome alone . Patients achieve complete response ( CR ) continue therapy 2 course documentation confirm CR . Patients achieve partial response ( PR ) continue therapy progression 2 course documentation stable PR . Patients stable disease continue therapy maximum 6 course . Cohorts 3-6 patient receive escalate dos lurtotecan liposome maximum tolerate dose ( MTD ) reach . The MTD define dose least 2 6 patient experience dose-limiting toxicity . Once MTD determine , 10 patient previously untreated solid tumor treat recommended phase II dose ( 1 dose MTD ) . Patients follow 4 week every 3 month 1 year . PROJECTED ACCRUAL : A total 20-25 patient accrue study within 12-15 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Lurtotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced and/or metastatic solid tumor refractory standard curative therapy curative therapy exist Clinically radiographically document disease No tumor marker elevation evidence disease No untreated brain meningeal metastases Previously treat stable CNS metastasis allow ( i.e. , evidence increase disease CT scan least 4 week ) Recommended phase II dose portion study : Previously untreated advanced and/or metastatic disease cisplatinbased regimen indicate ( e.g. , nonsmall cell lung cancer , small cell lung cancer , ovarian , head neck cancer ) At least one measurable lesion least 20 mm physical exam xray least 10 mm spiral CT scan PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) AST/ALT great 2.5 time ULN ( 5 time ULN document liver metastasis ) Renal : Creatinine great ULN OR Creatinine clearance least 60 mL/min Other : No great grade 1 neuropathy ototoxicity No prior concurrent malignancy within past 5 year except curatively treat basal squamous cell skin cancer cervical cancer ( recommend phase II dose ) No active uncontrolled infection No serious illness medical condition would preclude study No known hypersensitivity systemic liposomal formulation drug chemically relate study drug Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Chemotherapy Recovered prior immunotherapy Chemotherapy : See Disease Characteristics No 1 prior chemotherapy regimen ( adjuvant and/or metastatic ) except nonmyelosuppressive agent ( e.g. , signal transduction inhibitor immunotherapy ) At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin 4 week carboplatin ) recover At least 1 year since prior highdose chemotherapy marrow stem cell support No prior total cisplatin dose 300 mg/m2 No prior chemotherapy ( recommended phase II dose ) Endocrine therapy : Prior hormonal therapy allow Radiotherapy : At least 4 week since prior radiotherapy recover No prior radiotherapy 25 % bone marrow reserve , except lowdose nonmyelosuppression Surgery : Not specify Other : At least 4 week since prior experimental drug anticancer therapy recover No concurrent investigational anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage IV nasopharyngeal cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III basal cell carcinoma lip</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage III mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage III adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
	<keyword>ovarian sarcoma</keyword>
</DOC>